Biotech's Boom Suffers a Setback in March April 01, 2014 | Press Release
Investors Flock to Biotech March 03, 2014 | Press Release
Biotech IPOs Off to a Strong Start in 2014 February 03, 2014 | Press ReleaseSee all News
Burrill & Company and Infinity Group Form Joint Venture Focusing on Life Science Opportunities in ChinaOctober 12, 2010
SAN FRANCISCO and HONG KONG, Oct. 12 /PRNewswire/ -- Burrill & Company, a leading life sciences venture capital/private equity firm and Infinity Group, an RMB fund pioneer and the leading cross border China dollar and RMB private equity fund announced today that they have established a strategic partnership . The mandate of the joint venture will be to pursue life science investment opportunities in China; Burrill and Infinity will co-invest as equal partners in US dollar and RMB investments.
Infinity's China expertise and network, currently spanning ten well developed cities in China, combined with Burrill & Company's US and global experience and networks create an unparalleled, China-focused, life sciences partnership. Under the terms of the partnership agreement, Burrill will establish headquarters for its China operations in Hong Kong where Infinity already has an established presence; it will also utilize all 10 of Infinity's offices in Greater China as well as its international offices located in the United States, Europe and Asia. Infinity will strengthen its presence in the United States through this cooperation, which is part of Infinity's strategy to enhance its position as a global life science fund bringing innovative technologies from Israel, the US and Europe to China.
"We are very excited about this joint venture as this partnership will be able to build upon our complementary focus areas internationally," said G. Steven Burrill, CEO, Burrill & Company, a San Francisco based global leader in life sciences with activities in private equity, venture capital, merchant banking and media. "We will be able to bring our venture capital/private equity operations with our focus on innovation to delivery in healthcare, as well as activities in life sciences publications and events to Infinity's extensive operations and networks in China."
"We have developed a unique and unparalleled network of partnerships in China in the past few years," said Mr. Amir Gal-Or, founder & China based managing partner of the Infinity Group. "We are enthusiastic about partnering with Burrill and the opportunity to leverage its international life sciences expertise throughout China."
About Burrill & Company
Founded in 1994, Burrill & Company is a San Francisco-based global leader in life sciences with activities in Venture Capital, Private Equity, Merchant Banking and Media. The Burrill family of venture capital funds has over $1 billion under management and its merchant banking business is one of the industry leaders assisting life science companies to identify, negotiate and close strategic transactions. Burrill is also the creator, sponsor and facilitator of leading industry conferences worldwide and publisher of a range of bio-intelligence reports including the monthly Burrill Report (www.burrillreport.com) and annual "State of the Industry" report.
Contact: H. Michael Keyoung, MD, PhD, Managing Director, Burrill Pan-Asia, Burrill & Company, 415-591-5400, Email: firstname.lastname@example.org; www.burrillandco.com
About Infinity Group
Infinity Group is an RMB fund pioneer and the leader in cross border China RMB and dollar private equity funds. It is also the founder of the Infinity IP Bank, the hub for IP development and commercialization in China. Infinity Group currently manages eleven funds, nine in China. Infinity has a portfolio of 45 companies and has made 22 successful exits. Infinity, which has the greatest number of RMB funds in China, was founded by the IDB Group (the largest conglomerate in Israel) and the China Development Bank. Infinity serves as a bridge for Chinese companies that want to integrate technology and know-how to compete internationally and non-Chinese companies, with proven technology, seeking to capitalize on the Chinese market. Sectors of focus include: medical device, pharma and healthcare services, information technology, agriculture, materials, as well as water and clean technology and energy. Recent high profile activities include investments in United Water Corporation (Shanghai, China) and Weigo (Shangdong, China), as well as exits from Tegrity, Orsus, FuturaGene and Teledata Networks. Other China-related exits include Shellcase, Nanomotion, and a partial exit from Digital China. Infinity has offices in Beijing, Changzhou, Chengdu, Harbin, Hong Kong, Jining, New York, Ningbo, Shanghai, Shijiazhuang Suzhou, Tel Aviv and Tianjin. For more information: www.infinity-equity.com or please contact Marjie Hadad at email@example.com or call +972-54-536-5220.